This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1111/
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33432502
rdf:type
wikibase:Item
schema:description
научни чланак artículo científico publicado en 2004 мақолаи илмӣ tudományos cikk 2004年论文 article scientifique (publié 2004) mokslinis straipsnis naučni članak articolo scientifico სამეცნიერო სტატია article scientific vedecký článok 2004年論文 2004年论文 scienca artikolo artikulong pang-agham 2004年論文 vědecký článek επιστημονικό άρθρο wetenschappelijk artikel vitenskapelig artikkel наукова стаття, опублікована в жовтні 2004 teaduslik artikkel 2004 nî lūn-bûn научна статия 2004년 논문 wissenschaftlicher Artikel מאמר מדעי ২০০৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ videnskabelig artikel (udgivet 2004) vitskapeleg artikkel 2004年论文 мақолаи илмӣ bilimsel makale articol științific bài báo khoa học tieteellinen artikkeli 2004年論文 2004年论文 مقالة علمية artigo científico artigo científico (publicado na 2004) 2004年の論文 scientific article научная статья บทความทางวิทยาศาสตร์ vetenskaplig artikel 2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած 2004 թվականի հոտեմբերին հրատարակված գիտական հոդված artikull shkencor 2004年论文 2004年論文 artigo científico (publicado na 2004) سائنسی مضمون 2004年论文 2004年論文 научни чланак artículu científicu espublizáu en 2004 مقالهٔ علمی artykuł naukowy article científic
p:P577
wds:Q33432502-73B5CE8B-BABD-4CD5-AF2D-0215AE51ACF1
wdt:P577
2004-10-01T00:00:00Z
p:P2860
wds:Q33432502-19755D2B-93C9-4B66-92DF-8096C0FCB52A
wdt:P2860
wd:Q41445391
p:P2093
wds:Q33432502-EADB14E1-1E01-4787-9049-707C2F91F70D wds:Q33432502-897E9401-EDBD-48EA-ABA4-AD5AAEAC8DE1 wds:Q33432502-7CFB436A-1665-4A37-A299-EF3B9E09F58C wds:Q33432502-5C1C152D-8EF0-4AB5-9A95-115843CE0AC2 wds:Q33432502-68FC7DA4-E1D4-41BD-BCB2-CD02D84EA4FE wds:Q33432502-54D11158-07A0-45DF-99A6-274960D449F9 wds:Q33432502-02260999-DD95-4FED-95E5-BE6B5A2B66C4
wdt:P2093
Richard Isaacs Johnson J Liu Andrew Simpson Michael Findlay Philip Kestell Greta Riley Stephen Ackland
rdfs:label
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients
skos:prefLabel
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients
schema:name
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients
p:P50
wds:Q33432502-92C36F89-A662-4606-8E75-8EBFEFAB57C2
wdt:P50
wd:Q56999095
p:P1476
wds:Q33432502-2CB8C8BF-99B9-4B15-B248-2C299B941E2E
wdt:P1476
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients
p:P304
wds:Q33432502-C4EC09DD-F462-49B0-8C96-3D57F1698479
wdt:P304
677-682
p:P31
wds:Q33432502-B7BB344E-E7B9-4E7B-8611-93047AE12310
wdt:P31
wd:Q13442814
p:P921
wds:Q33432502-74D1B674-5248-4332-AC7B-A63584A01B0E
wdt:P921
wd:Q5452194
p:P698
wds:Q33432502-0074B286-892E-4237-8B69-1AB07566289D
wdtn:P698
n9:15554907
wdt:P698
15554907
p:P1433
wds:Q33432502-80935652-E114-4C0B-9960-91EAECB0F890
wdt:P1433
wd:Q5133807
p:P433
wds:Q33432502-E205E044-5631-40B7-9819-C6326D4D843E
p:P478
wds:Q33432502-B63C8559-C233-44C7-84A6-36A863BEEEEB
wdt:P433
10
wdt:P478
31
p:P356
wds:Q33432502-DF03CFBC-DE51-4BC3-9F0A-50A76201FD89
wdtn:P356
n12:J.1440-1681.2004.03065.X
wdt:P356
10.1111/J.1440-1681.2004.03065.X